Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioNTech SE
  6. News
  7. Summary
    BNTX   US09075V1026


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Press Release: Pfizer and BioNTech Receive First U.S. Authorization for Emergency Use of COVID-19 Vaccine in Adolescents

05/11/2021 | 02:30am EDT
   -- In a Phase 3 trial, the vaccine was 100% effective and generally well 
      tolerated in participants aged 12 to 15 years 
   -- Data also submitted to European Medicines Agency (EMA) and other global 
      regulators, with additional authorizations expected in coming weeks 
   NEW YORK and MAINZ, GERMANY, May 11, 2021 -- 
Pfizer Inc. (NYSE: PFE) and 
BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food and Drug 
Administration (FDA) has expanded the Emergency Use Authorization (EUA) 
for their COVID-19 vaccine to include individuals 12 to 15 years of age. 
This is the first COVID-19 vaccine authorized in the U.S. for use in 
this age group. 
   "Today's expansion of our EUA represents a significant step forward in 
helping the U.S. government broaden its vaccination program and help 
protect adolescents before the start of the next school year," said 
Albert Bourla, Chairman and Chief Executive Officer, Pfizer. "We are 
grateful to all of our clinical trial volunteers and their families, 
whose courage helped make this milestone possible. Together, we hope to 
help bring a sense of normalcy back to young people across the country 
and around the world." 
   The FDA based its decision on data from a pivotal Phase 3 clinical trial, 
which enrolled 2,260 participants aged 12 to 15 years. Topline results 
from this trial, 
announced on March 31, 2021, showed a vaccine efficacy of 100% in 
participants with or without prior SARS-CoV-2 infection and robust 
antibody responses. In the trial, the vaccine was also generally well 
tolerated. Participants will continue to be monitored for long-term 
protection and safety for an additional two years after their second 
   As a next step following today's FDA decision, the U.S. Centers for 
Disease Control and Prevention's (CDC) Advisory Committee on 
Immunization Practices (ACIP) will meet to discuss recommendations for 
use of the Pfizer-BioNTech COVID-19 Vaccine in adolescents 12 to 15 
years of age based on the amended EUA. 
   "Since securing the EUA in December for individuals 16 years and older, 
we have been working tirelessly to get our COVID-19 vaccine authorized 
around the world so that governments can provide it to as many people as 
possible," said Ugur Sahin, M.D., CEO and Co-founder of BioNTech. "Our 
work is not yet complete, as we continue our research into the use of 
our vaccine in pediatric populations. Our goal is to submit data for 
pre-school and school-age children in September." 
   Pfizer and BioNTech have submitted the data in adolescents 12 to 15 
years of age for scientific peer review for potential publication. The 
data also have been submitted to other regulators around the world, 
including the European Medicines Agency (EMA). 
   In addition, the pediatric study evaluating the safety and efficacy of 
the Pfizer-BioNTech COVID-19 vaccine in children 6 months to 11 years of 
age is ongoing. Pfizer and BioNTech expect to have definitive readouts, 
and subject to the data generated, submit for an EUA or a variation to 
Conditional Marketing Authorizations for two cohorts, including children 
2-5 years of age and 5-11 years of age, in September. The readout and 
submission for the cohort of children 6 months to 2 years of age are 
expected in the fourth quarter. 
   The Pfizer-BioNTech COVID-19 vaccine, which is based on BioNTech 
proprietary mRNA technology, was developed by both BioNTech and Pfizer. 
BioNTech is the Marketing Authorization Holder in the European Union, 
and the holder of emergency use authorizations or equivalents in the 
United States (together with Pfizer), United Kingdom, Canada and other 
countries in advance of a planned application for full marketing 
authorizations in these countries. 
   The Pfizer-BioNTech COVID-19 vaccine has not been approved or licensed 
by the U.S. Food and Drug Administration (FDA), but has been authorized 
for emergency use by FDA under an Emergency Use Authorization (EUA) to 
prevent Coronavirus Disease 2019 (COVID-19) caused by severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) for use in individuals 
12 years of age and older. The emergency use of this product is only 
authorized for the duration of the declaration that circumstances exist 
justifying the authorization of emergency use of the medical product 
under Section 564 (b) (1) of the FD&C Act unless the declaration is 
terminated or authorization revoked sooner. Please see Emergency Use 
Authorization (EUA) Fact Sheet for Healthcare Providers Administering 
Vaccine (Vaccination Providers) and Full EUA Prescribing Information 
available at 
   The Pfizer-BioNTech COVID19 vaccine is authorized for use under an 
Emergency Use Authorization (EUA) for active immunization to prevent 
coronavirus disease 2019 (COVID-19) caused by severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 years of age and 
   -- Do not administer Pfizer-BioNTech COVID-19 vaccine to individuals with 
      known history of a severe allergic reaction (eg, anaphylaxis) to any 
      component of the Pfizer-BioNTech COVID-19 vaccine 
   -- Appropriate medical treatment used to manage immediate allergic reactions 
      must be immediately available in the event an acute anaphylactic reaction 
      occurs following administration of Pfizer-BioNTech COVID-19 vaccine 
   -- Monitor Pfizer-BioNTech COVID-19 vaccine recipients for the occurrence of 
      immediate adverse reactions according to the Centers for Disease Control 
      and Prevention guidelines ( 
   -- Syncope (fainting) may occur in association with administration of 
      injectable vaccines, in particular in adolescents. Procedures should be 
      in place to avoid injury from fainting 
   -- Immunocompromised persons, including individuals receiving 
      immunosuppressant therapy, may have a diminished immune response to the 
      Pfizer-BioNTech COVID-19 vaccine 
   -- The Pfizer-BioNTech COVID-19 vaccine may not protect all vaccine 
   -- In clinical studies, adverse reactions in participants 16 years of age 
      and older included pain at the injection site (84.1%), fatigue (62.9%), 
      headache (55.1%), muscle pain (38.3%), chills (31.9%), joint pain (23.6%), 
      fever (14.2%), injection site swelling (10.5%), injection site redness 
      (9.5%), nausea (1.1%), malaise (0.5%), and lymphadenopathy (0.3%) 
   -- In a clinical study, adverse reactions in adolescents 12 through 15 years 
      of age included pain at the injection site (90.5%), fatigue (77.5%), 
      headache (75.5%), chills (49.2%), muscle pain (42.2%), fever (24.3%), 
      joint pain (20.2%), injection site swelling (9.2%), injection site 
      redness (8.6%), lymphadenopathy (0.8%), and nausea (0.4%) 
   -- Severe allergic reactions, including anaphylaxis, and other 
      hypersensitivity reactions, diarrhea, vomiting, and pain in extremity 
      (arm) have been reported following administration of the Pfizer-BioNTech 
      COVID-19 vaccine outside of clinical trials. Additional adverse reactions, 
      some of which may be serious, may become apparent with more widespread 
      use of the Pfizer-BioNTech COVID-19 vaccine 
   -- Available data on Pfizer-BioNTech COVID-19 vaccine administered to 
      pregnant women are insufficient to inform vaccine-associated risks in 
   -- Data are not available to assess the effects of Pfizer-BioNTech COVID-19 
      vaccine on the breastfed infant or on milk production/excretion 
   -- There are no data available on the interchangeability of the 
      Pfizer-BioNTech COVID-19 vaccine with other COVID-19 vaccines to complete 
      the vaccination series. Individuals who have received one dose of 
      Pfizer-BioNTech COVID-19 vaccine should receive a second dose of 
      Pfizer-BioNTech COVID-19 vaccine to complete the vaccination series 
   -- Vaccination providers must report Adverse Events in accordance with the 
      Fact Sheet to VAERS online at https://vaers.hhs.gov/reportevent.html. For 
      further assistance with reporting to VAERS call 1-800-822-7967. The 
      reports should include the words "Pfizer-BioNTech COVID-19 Vaccine EUA" 
      in the description section of the report 
   -- Vaccination providers should review the Fact Sheet for Information to 
      Provide to Vaccine Recipients/Caregivers and Mandatory Requirements for 
      Pfizer-BioNTech COVID-19 vaccine Administration Under Emergency Use 
   Before administration of Pfizer-BioNTech COVID-19 vaccine, please see 
Emergency Use Authorization (EUA) Fact Sheet for Healthcare Providers 
Administering Vaccine (Vaccination Providers) including Full EUA 
Prescribing Information available at 
   About Pfizer: Breakthroughs That Change Patients' Lives 

(MORE TO FOLLOW) Dow Jones Newswires

May 11, 2021 02:30 ET (06:30 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE 4.60% 236.49 Delayed Quote.190.10%
CLASS III MILK FUTURES (DC) - CMG (ELECTRONIC)/C1 0.00% 17.33 End-of-day quote.9.56%
CLASS IV MILK?FUTURES (GDK) - CMG (ELECTRONIC)/C1 0.00% 16.44 End-of-day quote.19.51%
DJ INDUSTRIAL 0.20% 33945.58 Delayed Quote.10.69%
DRY WHEY?FUTURES (DY) - CMG (ELECTRONIC)/C1 0.00% 64.7 End-of-day quote.46.21%
NASDAQ COMP. 0.79% 14253.268071 Delayed Quote.9.72%
NONFAT DRY MILK FUTURES (GNF) - CMG (ELECTRONIC)/C1 0.00% 127 End-of-day quote.12.49%
PFIZER, INC. 0.48% 39.61 Delayed Quote.7.61%
S&P GSCI CLASS III MILK (USD) -0.94% 127.7904 Delayed Quote.-2.86%
All news about BIONTECH SE
04:49pBIONTECHá : 139,683,231Number of shares for which valid votes were cast (= 56.71..
04:21pNOVARTISá : aims to bottle more than 50 mln doses of BioNTech COVID-19 vaccine i..
01:41pBIONTECHá : AGM Presentation CEO and COO/CFO
01:39pBIONTECHá : AGM Voting Results
01:39pBIONTECHá : Speech of Prof. Dr. Ugur Sahin (CEO)
01:39pBIONTECHá : Speech of Dr. Sierk Poetting (COO/CFO)
11:11aEuropean ADRs Move Lower in Tuesday Trading
10:50aPFIZERá : BioNTech considers possible dividend next year
07:08aEU Approves Two More Manufacturing Sites for Pfizer-BioNTech Covid Vaccine
06/21Foxconn to Donate COVID-19 Vaccines to Taiwan Government
More news
Sales 2021 12 387 M 14 774 M 14 774 M
Net income 2021 7 065 M 8 426 M 8 426 M
Net cash 2021 7 669 M 9 147 M 9 147 M
P/E ratio 2021 7,00x
Yield 2021 -
Capitalization 47 849 M 57 117 M 57 068 M
EV / Sales 2021 3,24x
EV / Sales 2022 3,23x
Nbr of Employees 2 200
Free-Float 87,3%
Duration : Period :
BioNTech SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 13
Last Close Price 198,12 €
Average target price 148,08 €
Spread / Average Target -25,3%
EPS Revisions
Managers and Directors
Ugur Sahin Chief Executive Officer
Sierk P÷tting Chief Operating & Financial Officer
Helmut Jeggle Chairman-Supervisory Board
Ízlem TŘreci Chief Medical Officer
Christoph Huber Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
BIONTECH SE190.10%54 605
WUXI APPTEC CO., LTD.24.70%66 143
BEIGENE, LTD.28.69%30 138